Lead Product(s): ASC41,ASC40
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2020
ASC41 is expected to be used in combination with ASC40, another innovative drug of the Company, for treatment of NASH.